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Abstract 
Objectives - The aim was to investigate whether nebivolol has added effects on left ventricular (LV) 
dysfunction and remodelling early after MI beyond its β1-receptor blocking properties.  
Background - Nebivolol is a third-generation selective β1-adrenoreceptor antagonist that stimulates 
endothelial cell nitric oxide (NO) production and prevents vascular NAD(P)H oxidase activation. Both, 
endothelial NO synthase-derived NO production and NAD(P)H oxidase activation are critical 
modulators of LV dysfunction early after myocardial infarction (MI).  
Methods - Mice with extensive anterior MI (n=90) were randomized to treatment with nebivolol (10 
mg/kg/day), metoprolol-succinate (20 mg/kg/day), or placebo for 30 days starting on day 1 after 
surgery.  
Results - Infarct size was similar among the groups. Both β1-adrenergic receptor antagonists caused 
a similar decrease in heart rate. Nebivolol therapy improved endothelium-dependent vasorelaxation 
and increased early endothelial progenitor cells 4 weeks after MI as compared to metoprolol and 
placebo. Nebivolol, but not metoprolol inhibited cardiac NAD(P)H oxidase activation after MI as 
detected by electron spin resonance spectroscopy (ESR) analysis. Importantly, nebivolol, but not 
metoprolol improved LV dysfunction 4 weeks after MI (LV ejection fraction: nebivolol vs. metoprolol vs. 
placebo 32±4 vs. 17±6 vs. 19±4 %; nebivolol vs. metoprolol: P<0.05) and was associated with 
improved survival 4 weeks post MI as compared to placebo. Nebivolol had a significantly more 
pronounced inhibitory effect on cardiomyocyte hypertrophy after MI as compared to metoprolol.  
Conclusions - Nebivolol improves LV dysfunction and survival early after MI likely beyond the effects 
provided by conventional β1-receptor blockade. Nebivolol induced effects on NO mediated, endothelial 
function, early endothelial progenitor cells and inhibition of myocardial NAD(P)H oxidase likely 
contribute to these beneficial effects of nebivolol early after MI. 
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Abbreviation list 
CSA Cross sectional area 
EDD End-diastolic diameter 
EF Ejection fraction 
eNOS Endothelial nitric oxide synthase 
EPC Endothelial progenitor cells 
ESD End-systolic diameter 
ESR Electron spin resonance spectroscopy 
FS Fractional shortening 
HPF High power field 
LV Left ventricular, left ventricle 
MI Myocardial infarction 
NO Nitric oxide 
RR Blood pressure 
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Introduction 
β1-Adrenergic receptor blockers have become a hallmark
 
in the management of patients after acute 
myocardial
 
infarction as well as in the treatment of chronic heart failure (1). In contrast to conventional 
β1-selective adrenergic receptor antagonists such as metoprolol-succinate the βselective adrenergic 
receptor blocker nebivolol has been shown to possess additional actions, in particular, to stimulate 
endothelial cell NO production (2-4), which is thought to be mediated by β3-receptor activation (5-7) 
and by interaction with the estrogen receptor (8). The release of the endothelium-derived
 
relaxing 
factor NO has been suggested to mediate vasodilatory properties of nebivolol, since nebivolol induced 
vasodilation is almost
 
completely blocked by inhibitors of the NO synthase (3). Moreover, 
administration of nebivolol has been shown to prevent hypercholesterolemia induced uncoupling of 
endothelial NO synthase (9) and to restore NO availability in endothelial cells obtained from black 
Americans (10). Furthermore, nebivolol has been suggested to exert systemic antioxidant effects (11) 
and to inhibit inflammatory cell NAD(P)H oxidase activation (9) and vascular NAD(P)H oxidase 
activation in response to angiotensin-II (12).  
Importantly, accumulating evidence suggests a critical role of both, endothelial nitric oxide synthase-
derived nitric oxide availability (13-15) and NAD(P)H oxidase activation for left ventricular (LV) 
dysfunction and cardiomyocyte hypertrophy early after myocardial infarction (MI) (16-18). In this 
respect, we have recently observed that statins improve endothelium-dependent vasodilation, left 
ventricular dysfunction and survival after experimental myocardial infarction that was critically 
dependent on their effect on endothelial NO synthase (eNOS), suggesting that increased eNOS-
derived NO production may exert beneficial effects on LV dysfunction and survival after MI (13,14,19). 
Furthermore, endothelial or cardiomyocyte-targeted overexpression of eNOS resulted in improved LV 
function after MI (13,19). Vice versa, suppression of eNOS-dependent NO production resulted in an 
augmented left ventricular dysfunction (15), reduced myocardial neovascularisation (20), and impaired
 
mobilization
 
of early endothelial progenitor cells (EPCs) (14,19).  
In addition, we and others have observed that prevention of NAD(P)H oxidase activation after 
myocardial infarction improved LV dysfunction after MI, supporting the concept that NAD(P)H oxidase 
activation contributes importantly to LV dysfunction early after MI (16,17).  
The present study was therefore designed to examine the effect of nebivolol therapy as compared to 
metoprolol-succinate or placebo on endothelium-dependent, NO mediated vasodilatation, early 
endothelial progenitor cell (EPC) mobilization, as well as myocardial NAD(P)H oxidase activation as 
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analysed by electron resonance spectroscopy (ESR) early after myocardial infarction. Moreover, we 
examined the effect of nebivolol and metoprolol-succinate therapy on LV dysfunction, survival and 
cardiomyocyte hypertrophy early after myocardial infarction.  
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Methods 
Animals, MI, and Experimental Protocol  
The local committee on animal research approved all procedures involving experimental animals and 
all procedures were performed in accordance with the Guide for the Care and Use of Laboratory 
Animals as adopted by the U.S. National Institutes of Health (NIH).  
In male C57BL/6J mice, aged 14 to 16 weeks, myocardial infarction was induced by
 
permanent 
ligation of the left anterior descending coronary
 
artery as described previously (14,16). On the first day, 
24 hours after
 
MI, these mice were randomized into 3 groups (n=30 each): (I) treatment with nebivolol 
(10 mg kg
-1
 d
-1
), (II) metoprolol-succinate (20 mg kg
-1
 d
-1
), or (III) inert vehicle given orally via gastric 
gavage for 30 days starting on day 1 after surgery. Sham-operated mice (n=30) served as controls. 
These doses of nebivolol and metoprolol-succinate were used to achieve similar reductions in heart 
rate (as observed in preliminary experiments).  
Furthermore, in additional experiments myocardial infarction was induced in eNOS
-/-
 mice that were 
randomized on day 1 to nebivolol or vehicle therapy (n=10 each) using the above dose. Sham-
operated eNOS
-/- 
mice (n=10) served as controls. 
 
Studies of Endothelium-Dependent, NO-Mediated Vasorelaxation 
Endothelium-dependent, NO mediated vasorelaxation in response
 
to acetylcholine and endothelium-
independent relaxation in response
 
to nitroglycerin were studied in ring segments of thoracic aortas
 
as 
described previously (14,21,22). Notably, it has been shown that
 
acetylcholine responses are lacking 
in eNOS-deficient mice (21,23) which indicates that these responses are dependent on endothelial 
nitric oxide synthase. 
 
Early EPC Culture Assay 
Early EPCs were cultured as described in detail previously (14,24-26). In brief, mononuclear cells 
were isolated from 1 mL of
 
peripheral blood by density gradient centrifugation with Histopaque
 
(Sigma) 
(27), seeded on tissue culture coverslips (9x10
5
 cells)
 
coated with rat vitronectin (Sigma) in endothelial
 
basal medium (endothelial growth medium-2 MV, Clonetics), and
 
supplemented with EGM-2 MV single 
quots (containing fetal bovine
 
serum, human vascular endothelial growth factor-A, human fibroblast
 
growth factor-B, human epidermal growth factor, insulin-like
 
growth factor-1, and ascorbic acid in 
appropriate amounts).
 
After 4 days in culture, nonadherent cells were removed by washing
 
with 
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phosphate buffered saline. The cell culture was maintained
 
through day 7, and fluorescence chemical 
detection was performed.
 
To detect the uptake of 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine–labeled
 
acetylated LDL (acLDL-DiI; Molecular Probes), cells were 
incubated
 
with acLDL-DiI (6 µg/mL, 37°C, 2 hours). Cells were
 
then fixed with 1% paraformaldehyde 
for 10 minutes and incubated
 
with fluorescein-labeled Griffonia simplicifolia lectin I (BS-1
 
lectin, Vector 
Labs) for 1 hour. After being stained, samples
 
were analyzed with an inverted fluorescence 
microscope (Leica),
 
and double-stained cells for both BS-1 lectin and acLDL-DiI
 
were counted as early 
EPCs in at least 4 randomly selected HPFs (28).  
 
Histomorphometric Analysis and Immunohistochemistry 
Tissue morphometry was
 
performed in a blinded fashion with the Quantimet 500MC digital
 
image 
analyzer. After in situ fixation, LV tissue slices were embedded in paraffin and cut into 4-μm sections 
as described previously (16,29). Mean cardiomyocyte cross sectional area or length, and  infarct size 
were determined in hematoxylin-eosin-stained sections or sections stained with antibodies recognizing 
wheat germ agglutinin to visualize myocyte boundaries (WGA; Vector) using the digital image analyzer 
as described previously (29-32). Nuclei were stained with DAPI. For measurements of the 
cardiomyocyte cross sectional area or cardiomyocyte length only cross gated cardiomyocytes 
respectively longitudinally sectioned cardiomyocytes were analysed. Furthermore, length of 
cardiomyocytes isolated from in situ formalin-fixed LV tissue was measured using the KOH method as 
described in detail previously (33). In brief, LV samples were cut into small pieces, placed overnight 
into a 12.5 mol/L KOH solution and transferred into phosphate buffer. Samples were then mixed using 
a vortexer, centrifuged and resuspended in 10% formaldehyde-phosphate buffer. Nuclei were stained 
by Mayers hemalaum solution, in order to differentiate between cell fragments and intact myocytes. 
Myocyte length (50 structurally intact myocytes / sample) was determined by using an Olympus BX51 
microscope and the software program Analysis 5.0. 
For immunohistochemistry analysis of capillary density
 
mid-LV specimens were obtained and capillary 
density was determined as described in detail previously (14). Sections were immunostained with the 
anti–platelet
 
and endothelial cell adhesion molecule-1 (CD31) rabbit polyclonal antibody (H-300, Santa 
Cruz) and detection of the primary antibody was performed using the avidin-biotin-peroxidase labelling 
system. Counterstaining was performed with hematoxylin, and results are expressed as capillaries per 
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cardiomyocytes. At least 6 high power fields (HPFs) of cross sectioned areas per infarct border zone 
were examined by an investigator blinded to the treatment group. 
 
Echocardiographic Measurements 
Echo analysis was performed under light anesthesia (ketamine
 
100 mg/kg, xylazine 1.25 mg/kg, and 
atropine 0.6 mg/kg IP) and
 
spontaneous respiration with a commercially available ultrasound
 
system 
(ATL5000 CV) with a linear 15-MHz high-frequency transducer
 
as described previously (14,16). The 
investigator (A.S.) was blinded
 
to the experimental group. 
 
Measurement of Myocardial NAD(P)H Oxidase Activity by Electron Spin Resonance 
Spectroscopy Analysis 
Activity of NAD(P)H oxidase was determined in remote LV myocardium (50 μg protein) by ESR 
spectroscopy as described previously by using the spin probe 1-hydroxy-3 carboxypyrrolidine (CP-H) 
and a MiniScope ESR spectrometer (Magnettech) (16,34). The ESR settings were the following: field 
center: 3367.67 G; field sweep width: 108.92 G; microwave frequency: 9.82 GHz; microwave power: 
20 mW; magnetic field modulation frequency: 100 kHz; modulation amplitude: 2 G. The intensity of 
ESR spectra was quantified after subtraction of the ESR signal of samples without NAD(P)H (obtained 
for each sample). 
 
Measurement of Superoxide Production in Human Aortic Endothelial Cells by Electron Spin 
Resonance Spectroscopy Analysis 
Human aortic endothelial cells (HAECs) purchased from Clonetics
 
were grown according to standard 
procedures. Serum-starved HAECs were exposed to metoprolol (10 µmol/L), nebivolol (10 µmol/L) or 
the solvent after a 60 minute
 
preincubation with various pharmacological modulators, i.e., bupranolol
 
(10 µmol/L), or nadolol (10 µmol/L) as described in detail previously (6).  
Superoxide production in HAECs in response to 24h angiotensin-II stimulation was measured by 
electron spin resonance (ESR) spectroscopy and the spin trap CP-H as described in detail previously 
(16,34).  
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Blood Pressure Measurements 
Systolic blood pressure (SBP) was measured by a computerized non-invasive tail cuff system (Blood 
Pressure Analysis System BP-200, Visitech Systems, Apex, NC, USA) as described previously 
(14,22).  
 
Statistical Analysis  
All data are expressed as mean ± SEM. Statistical analysis was performed using analysis of variance 
(ANOVA) followed by Newman-Keuls multiple comparison test. For the comparison of two groups 
(eNOS-deficient mice), the 2-tailed unpaired Student t-test was used. Comparison of survival was 
performed
 
using Kaplan-Meier analysis and log-rank test. A P value of < 0.05 was considered 
statistically significant. Data were analyzed by using GraphPad Prism 4.03™. 
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Results 
Effect of Nebivolol and Metoprolol-Succinate Treatment on Endothelium-Dependent, NO 
Mediated Vasodilation after Myocardial Infarction 
In sham-operated mice, acetylcholine produced endothelium-dependent
 
relaxations of 93±10%. These 
responses were
 
substantially impaired in aortas of WT mice 4 weeks after MI (21±4%; P<0.05; Figure 
1A). Nebivolol treatment markedly
 
improved endothelium-dependent vasodilation in response to 
acetylcholine
 
in mice after MI (55±7%, P<0.05 vs. Placebo), whereas metoprolol had no effect 
(21±3%, P=n.s. vs. vehicle; Figure 1A). In contrast,
 
endothelium-independent vasodilation in response 
to nitroglycerin
 
was not impaired in mice after MI and was neither changed by nebivolol nor by 
metoprolol treatment (Figure 1B). In eNOS
–/–
 mice, no endothelium-dependent
 
vasodilation in 
response to acetylcholine was observed, indicating
 
that these responses are dependent on endothelial 
NO synthase (data not shown). 
 
Effect of Nebivolol and Metoprolol-Succinate Treatment on Early EPCs after MI 
Increasing evidence suggests that endothelial nitric oxide synthase activation plays a critical role for 
mobilization of early endothelial progenitor cells (14,35). However,
 
it is not known whether early EPC 
numbers are altered by β-blocker treatment in the presence
 
of an ischemic stimulus. Notably, nebivolol 
therapy markedly augmented early EPCs as compared to placebo (Figure 2A, B). In contrast, 
metoprolol-succinate treatment had no significant effect on early EPC numbers as compared to 
vehicle (Figure 2A, B). As shown in Figure 2D, nebivolol therapy did not change early EPC numbers in 
eNOS
–/–
 mice, suggesting that this response is dependent on endothelial NO synthase. 
 
Effect of Nebivolol and Metoprolol-Succinate Treatment on Myocardial Capillary Density after 
MI 
The effect of nebivolol and metoprolol-succinate therapy on capillary density after MI was examined in 
at least 6 representative high power fields (HPFs) of the infarct border zone. Nebivolol, but not 
metoprolol-succinate therapy, resulted in a significant increase in capillary density in the infarct border 
zone in
 
WT mice after MI (Figure 2C). In contrast, nebivolol therapy had no effect on capillary density
 
in eNOS
–/–
 mice after (Figure 2E).  
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ESR Spectroscopic Analysis of Myocardial NAD(P)H Oxidase Activity after MI 
NAD(P)H oxidase activation has been shown to play a pivotal role for cardiomyocyte hypertrophy and 
LV dysfunction after MI (16,17). Furthermore, nebivolol has been shown to inhibit vascular NAD(P)H 
oxidase activation in response to hyperlipidemia (9). We therefore examined the effect of nebivolol 
and metoprolol-succinate therapy on myocardial NAD(P)H oxidase activity by using ESR 
spectroscopy. NAD(P)H oxidase activity in LV remote myocardium was markedly increased after 
myocardial infarction (Figure 3A, B). After 30 days treatment with nebivolol, but not with metoprolol, 
myocardial NAD(P)H oxidase activity was substantially reduced as assessed by electron spin 
resonance spectroscopy, indicating a suppression of myocardial NAD(P)H oxidase activation by 
nebivolol after MI (Figure 3A, B). 
 
Effect of Nebivolol and Metoprolol on Cardiomyocyte Hypertrophy and Cardiomyocyte Length 
after MI  
After myocardial infarction we observed cardiomyocyte hypertrophy as indicated by increased left 
ventricular weight / body weight ratio and increased cardiomyocyte length and cross sectional
 
area 
(CSA) in the remote myocardium (Figure 4A-D, Table 1). Whereas both β-blocker therapies reduced 
cardiomyocyte hypertrophy after MI, treatment with nebivolol had a significantly more pronounced 
inhibitory effect on left ventricular weight / body weight and cardiomyocyte cross sectional area as 
compared to metoprolol (P<0.05 vs. metoprolol, Figure 4A; P<0.001 vs. metoprolol, Table 1). In 
eNOS
–/–
 mice, the response of nebivolol therapy on LV mass and hypertrophy was attenuated as 
compared to wild type mice (Table 2), suggesting that this effect is at least partly dependent on 
endothelial NO synthase. 
Our data suggest that cardiomyocyte lengthening contributed to the observed LV weight / body mass 
differences after myocardial infarction, i.e. measurements of cardiomyocyte length of isolated 
cardiomyocytes by using the KOH method indicated an increase of cardiomyocyte length after 
myocardial infarction that was significantly attenuated by both β-blockers after MI (Figure 4B). The 
measurements of cardiomyocyte length of in situ fixed cardiac samples indicated a cardiomyocyte 
lengthening after MI that was reduced to a significantly greater extent by nebivolol as compared to 
metoprolol-succinate therapy (Figure 4C, D). A similar trend for a more pronounced effect of nebivolol 
therapy on cardiomyocyte length was observed by measurements of isolated cardiomyocytes using 
the KOH method that, however, did not reach statistical significance (Figure 4B).  
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Effect of Nebivolol and Metoprolol on LV Dysfunction after MI 
LV ejection fraction was substantially reduced
 
4 weeks
 
after MI as compared with sham-operated 
animals. Notably, nebivolol, but not metoprolol therapy significantly improved fractional shortening and 
LV ejection fraction 4 weeks after MI (Figure 5A-C, Table 1), suggesting that nebivolol therapy is 
associated with an early beneficial effect on LV function after MI. This effect of nebivolol therapy was 
not observed in eNOS
–/–
 mice after myocardial infarction, suggesting that the eNOS is involved in this 
effect (Figure 5D, E, Table 2). 
 
Survival post MI 
Nebivolol therapy was associated with a significantly improved survival at 4 weeks after MI as 
compared to vehicle therapy (P<0.05 vs. vehicle). The impact of metoprolol was not statistically 
significant (Figure 6).  
 
ESR Spectroscopic Analysis of Superoxide Production in HAECs 
The effect of blockade of specific β-adrenoreceptors
 
was tested on endothelial superoxide production 
in response to angiotensin-II, known to be dependent on NAD(P)H oxidase activation (36). As shown 
in Figure 7, pretreatment of HAECs with
 
the β1-2-blocker nadolol (10 µmol/L) had no effect
 
on nebivolol 
induced reduction of endothelial superoxide production, whereas
 
the complete β1-2-3-blocker 
bupranolol prevented
 
nebivolol’s effect on endothelial superoxide production in response to 
angiotensin-II, suggesting that the antioxidant effect of nebivolol was mediated via the β3-receptor. 
 
Infarct Size, Heart Rate and Blood Pressure 
Infarct size did not differ between the treatment groups (Table 1 and 2). Heart rate and blood pressure 
were similarly reduced by either β-blocker treatment (Table 1).  
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Discussion 
The present study demonstrates that nebivolol, a β1-selective adrenoreceptor antagonist with 
endothelial NO synthase stimulating properties attenuates LV dysfunction and cardiomyocyte 
hypertrophy early after myocardial infarction, associated with improved survival, that likely goes 
beyond the effects of conventional β-blockade. These effects of nebivolol therapy on LV dysfunction 
and cardiomyocyte hypertrophy early after myocardial infarction were largely blunted in eNOS-
deficient mice, supporting a critical role of eNOS in this respect. Thus, the present study supports the 
notion that beneficial effects of conventional β-blockade can be augmented by cardiac NO-dependent 
actions which may be related, at least in part, to activation of β3-receptors by nebivolol that may 
increase eNOS-dependent NO availability both, by preventing NAD(P)H oxidase activation and 
stimulation of endothelial NO synthase.  
Our present observations provide novel mechanistic insights concerning the early beneficial effects of 
nebivolol on LV function post MI. Nebivolol therapy exerted a beneficial effect on endothelium-
dependent, NO mediated vasodilation, early endothelial progenitor cell mobilization and myocardial 
neovascularisation after myocardial infarction, likely independent of its β1-receptor blocking effects, 
since it was not observed with the β1-selective adrenoreceptor antagonist metoprolol. Furthermore, in 
contrast to metoprolol-succinate, nebivolol inhibited myocardial NAD(P)H oxidase activation after MI. 
Moreover, our data suggest that the ability of nebivolol to reduce angiotensin-II induced NAD(P)H 
oxidase-dependent superoxide production is dependent on β3-receptor activation. In contrast to the 
neutral effect of β1-2-blockade
 
by nadolol, the
 
β1-2-3-blocker bupranolol significantly inhibited nebivolol’s 
effect on superoxide production.  
Several studies have firmly established the benefical effects of conventional β-blockers on LV 
remodelling processes post MI (37). However, whereas prolonged β-blocker therapy has been shown 
to improve LV function in patients with chronic heart failure and LV systolic dysfunction, the present 
study suggests that nebivolol exerts a beneficial effect on LV function and survival early after MI likely 
beyond β1-blockade that may be mediated by prevention of NAD(P)H oxidase activation and 
enhanced eNOS-dependent NO availability. 
Nebivolol is a third-generation highly selective β1-adrenoreceptor blocker. There is evidence that 
nebivolol in addition to its β1-adrenoreceptor blocking effects can stimulate endothelial nitric oxide 
production, which has been suggested to be mediated, at least in part, by a β3-agonistic effect (5,38). 
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Furthermore, nebivolol has been suggested to exert antioxidant effects, that have been attributed, at 
least in part, to prevent NAD(P)H oxidase activation in response to hyperlipidemia or angiotensin-II 
(9,12). Our data suggest that the β3-agonistic effect of nebivolol is involved in the inhibition of 
endothelial NAD(P)H oxidase activation. 
In the present study, nebivolol improved LV dysfunction and survival early after myocardial infarction, 
which was not observed with metoprolol-succinate therapy. In this respect, we and others have 
recently shown that both, endothelial NO synthase dependent NO production and NAD(P)H oxidase 
activation play a pivotal role for left ventricular dysfunction and survival early after myocardial 
infarction (13-17,19). In fact, statin induced improvement of LV function and survival early after MI 
were critically dependent on endothelial NO synthase, since they were not observed in eNOS-deficient 
mice (14). Moreover, endothelial or cardiomyocyte-targeted overexpression of eNOS resulted in 
improved LV function after MI, further suggesting an important role of eNOS-derived NO production for 
LV dysfunction early after MI (13,19). Similarly, drugs that act as NO enhancers have been recently 
shown to exert beneficial effects post MI (39), however in the absence of concomitant β-blocker 
therapy. Based on the present observations, it is conceivable that enhancement of NO activity on top 
of β-blockade provides additive effects early post MI.  
Moreover, in the present study we have observed that nebivolol therapy increased early endothelial 
progenitor cells and myocardial neovascularisation post MI in an eNOS-dependent manner, since this 
was not observed in eNOS-deficient mice. The observed association of an increase of early EPCs, 
improved myocardial neovascularisation and improved LV function after nevivolol therapy that were 
dependent on endothelial NO synthase does not prove a cause-and-effect relationship. However, 
there is recent evidence to support the concept that bone marrow derived progenitor cells may 
promote cardiac neovascularisation after MI and that this may contribute to an improved LV function 
after MI. Several recent studies have shown that administration of ex vivo expanded early EPCs 
increased myocardial neovascularisation at the infarct border and improved LV function (40-43). Cho 
et al. have reported that cardiac transplantation of early EPCs stimulated the host production of 
several angiogenic growth factors in the peri-infarct myocardium (43). Furthermore, Fazel et al. have 
observed that in mice with a mutation of the c-kit receptor, the mobilization of early endothelial 
progenitor cells after myocardial infarction was impaired that was associated with a reduced cardiac 
neovascularisation and augmented LV dysfunction early after myocardial infarction (44). Furthermore, 
eNOS-derived NO production has been shown to be critically important for the mobilization and 
 15 
angiogenic and endothelial repair capacity of mobilized early EPCs (14,24,35). More recently, eNOS 
was observed to be essential for the effects of bone marrow derived mononuclear cells on LV 
dysfunction after myocardial infarction, indicating an important role of eNOS containing cells for the 
effects on cardiac function after myocardial infarction (45). However, several potential local 
mechanisms have also been suggested whereby increased eNOS-dependent NO availability may 
improve myocardial neovascularisation including a reduced expression of growth inhibitors, ie, 
angiostatin (20), and an improved local vascular endothelial growth factor expression and activity that 
have been observed after overexpression of eNOS (46). Therefore, it is conceivable that both, the 
eNOS-dependent effects of nebivolol therapy on bone marrow derived progenitor cells and stimulation 
of local eNOS-dependent mechanisms may have contributed to increased myocardial 
neovascularisation and the observed beneficial effects on LV dysfunction early after MI.  
In the present study we have observed an inhibition of cardiac NAD(P)H oxidase activation early after 
MI in response to nebivolol, but not metorpolol therapy. Notably, we and others have recently 
demonstrated that prevention of NAD(P)H oxidase activation early after MI by using p47
phox
 or Nox2-
deficient mice attenuated cardiac hypertrophy and improved LV function and survival (16,17). These 
studies provide further evidence to suggest that the ancillary properties of nebivolol after MI observed 
in the present study may be useful in the early post infarction period and may provide potentially 
important beneficial cardiac effects beyond conventional β-blockade. Furthermore, our studies in 
endothelial cells suggest that nebivolol inhibits endothelial NAD(P)H oxidase activation via its β3-
receptor stimulating effect. Whereas prolonged β1-receptor blockade has been shown to exert 
beneficial effects on LV function in patients with chronic heart failure and reduced systolic function, the 
present study indicates that nebivolol possesses important additional beneficial effects likely 
independent of its β1-receptor blocking action, and likely related to its effects on endothelial NO 
synthase and the NAD(P)H oxidase system, in the early post infarction period.  
 
Limitations of the study: 
In the present study we have compared the effects of nebivolol therapy with metoprolol-succinate 
treatment, a selective β1-adrenoreceptor antagonist without endothelial NO synthase stimulating or 
NAD(P)H oxidase inhibiting properties, on LV dysfunction in mice early after myocardial infarction, and 
have observed that nebivolol therapy exerts additional effects on LV dysfunction early after MI as 
compared to metoprolol-succinate. As described above, our findings suggest that the effects of 
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nebivolol treatment on LV dysfunction early after MI were dependent on endothelial NO synthase, 
since there was no response in eNOS-deficient mice. However, this does not exclude that another 
third-generation β-blocker, in particular carvedilol, may also have ancillary effects, including effects on 
endothelial NO synthase derived NO availability that are relevant for LV dysfunction early after MI. In 
particular, we and others have observed that NADPH oxidase inhibition has the potential to increase 
eNOS-dependent NO availability (22,24). In two recent studies, both nebivolol and carvedilol (at higher 
concentrations) were observed to inhibit NADPH oxidase-dependent superoxide production in isolated 
neutrophils (9) and in heart membranes from angiotensin-II-infused rats (12) that was not detected 
after metoprolol or atenolol treatment. Furthermore, carvedilol but not metoprolol therapy has been 
observed to improve endothelial function in patients with type 2 diabetes (47). Our findings therefore 
do not exclude that another third-generation β-blocker, in particular carvedilol, may also have ancillary 
effects on eNOS-dependent NO availability that are relevant for LV dysfunction and remodelling after 
MI that remains to be determined in future studies and was beyond the scope of the present study. 
In the present study we have performed several measurements of LV hypertrophy post myocardial 
infarction, including determination of LV weight / body weight ratio, cardiomyocyte length and cross 
sectional area, since cardiomyocyte hypertrophy post myocardial infarction likely involves both, 
cardiomyocyte lengthening and an increase in cardiomyocyte width that can be stimulated by 
increased mechanical stretch and neurohumoral activation (48). The measurements of cardiomyocyte 
cross sectional area (CSA) likely need to be interpreted with caution due to its potential inherent 
limitations including analysis from selected representative cross sections of cardiomyocytes. While we 
cannot exclude that the cardiomyocyte CSA measurements may have overestimated the magnitude of 
differences between the groups, overall the different measurements performed to examine LV 
hypertrophy in the present study support the notion that both β-blockers reduced LV hypertrophy post 
MI and that this effect was more pronounced after nebivolol as compared to metoprolol-succinate 
treatment. 
In conclusion, the present study provides novel evidence that nebivolol treatment is associated with 
beneficial effects on left ventricular dysfunction, cardiomyocyte hypertrophy and survival early after 
myocardial infarction, likely independent of β1-receptor blocking effects, since it was not observed with 
metoprolol therapy. We speculate that improved NO-dependent vasodilation, mobilization of early 
endothelial progenitor cells and inhibition of myocardial NAD(P)H oxidase activation, as observed after 
nebivolol but not after metoprolol therapy, are contributing underlying mechanisms, that are involved in 
 17 
these beneficial ancillary properties of nebivolol in the early post MI period. This notion is supported by 
the observation that nebivolol therapy did not improve LV dysfunction early after MI in eNOS-deficient 
mice. 
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Figure Legends  
Figure 1: Endothelium-dependent and – independent Vasorelaxation  
A, Endothelium-dependent, NO mediated vasodilation in response to acetylcholine (Ach) in sham-
operated, vehicle, metoprolol and nebivolol treated mice 4 weeks after surgery. The significance test 
between groups shows a comparison at the highest concentration. B, Endothelium-independent 
vasorelaxation in response to nitroglycerine (NTG) in sham-operated, vehicle, metoprolol and 
nebivolol treated mice 4 weeks after surgery. 
 
Figure 2: Early EPCs and Capillary Density 
A, Early EPCs per HPF in sham-operated, vehicle, metoprolol and nebivolol treated mice 4 weeks 
after surgery (representative photographs are shown in B). C, Capillary density in the LV infarct border 
zone in vehicle, metoprolol and nebivolol treated mice 4 weeks after surgery. D, Early EPCs per HPF 
in vehicle and nebivolol treated eNOS deficient mice 4 weeks after surgery. E, Capillary density in the 
LV infarct border zone in vehicle and nebivolol treated eNOS-deficient mice 4 weeks after surgery 
(n=7-8). 
 
Figure 3: Cardiac NAD(P)H Oxidase Activity 
A, NAD(P)H oxidase activity in remote myocardium in sham-operated, vehicle, metoprolol and 
nebivolol treated mice 4 weeks after surgery as determined by ESR spectroscopy analysis 
(representative photographs are shown in B) (n=7). 
 
Figure 4: LV Weight and Cardiomyocyte Length  
A, LV weight / body weight in sham-operated, vehicle, metoprolol and nebivolol treated mice 4 weeks 
after surgery. B, Cardiomyocyte length as determined from isolated cardiomyocytes (KOH method) in 
sham-operated, vehicle, metoprolol and nebivolol treated mice 4 weeks after surgery. C, 
Cardiomyocyte length as determined by wheat germ agglutinin staining in sham-operated, vehicle, 
metoprolol and nebivolol treated mice 4 weeks after surgery (representative photographs are shown in 
D). (n=7) 
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Figure 5: LV Function 
A and B, LV fractional shortening and LV ejection fraction of sham-treated and post MI mice treated 
with vehicle, metoprolol or nebivolol as assessed by echocardiography. C, Representative 
photographs of M-mode echocardiography. D and E, LV fractional shortening and LV ejection fraction 
of eNOS-deficient mice after MI treated with vehicle or nebivolol. 
 
Figure 6: Survival 
Kaplan-Meier survival curves for mice after MI, treated with vehicle, metoprolol or nebivolol. 
Percentages of surviving mice were plotted. 
 
Figure 7: Superoxide Production  
ESR spectroscopy analysis of superoxide production in angiotensin-II stimulated HAECs. Effect of 
treatment with metoprolol (β1), nebivolol (β1), nadolol (β1,2), bupranolol (β1,2,3), n=12 in each 
experiment. 
 
 
Table 1      Wild type mice:  Echocardiographic, Hemodynamic and Morphometric Analyses 
 Sham 
WT 
Vehicle 
WT 
Metoprolol 
WT 
Nebivolol 
WT 
P 
(Metoprolol 
vs. 
Nebivolol) 
P  
(Vehicle  
vs. 
Metoprolol) 
P  
(Vehicle  
vs. 
Nebivolol) 
Echocardiography        
EDD [mm] 3.8 ± 0.1 6.3 ± 0.3 5.3 ± 0.3 5.2 ± 0.2 n.s. P<0.05 P<0.01 
ESD [mm] 2.4 ± 0.1 5.7 ± 0.3 4.9 ± 0.4 4.3 ± 0.2 n.s. n.s. P<0.01 
FS [%] 36.7 ± 1.1 9.6 ± 1.7 7.6 ± 3.3 16.6 ± 2.6 P<0.05 n.s. P<0.05 
EF [%] 55.9 ± 3.1 18.6 ± 3.7 17.1 ± 5.5 31.7 ± 3.5 P<0.05 n.s. P<0.05 
        
Weights and Morphometric Analysis 
LV [mg/g body weight] 
Body weight [g] 
 
3.6 ± 0.2 
29 ± 1.6 
 
6.2 ± 0.5 
33 ± 1.4 
 
4.8 ± 0.3 
26 ± 0.3 
 
4.0 ± 0.1 
29 ± 0.5 
 
P<0.05 
n.s. 
 
P<0.01 
P<0.001 
 
P<0.001 
P<0.05 
LV [mg] 
 
105 ± 6 
 
205 ± 21 
 
124 ± 9 
 
114 ± 4 
 
n.s. 
 
P<0.001 
 
P<0.001 
 
Cardiomyocyte cross sectional area 
[µm
2
] 
259 ± 12 553 ± 70 451 ± 8 362 ± 10 P<0.001 P<0.01 P<0.001 
Infarct size [%] n.a. 42 ± 3 41 ± 14 41 ± 12 n.s. n.s. n.s. 
Systolic RR [mmHg] 110 ± 3 
 
112 ± 2 106 ± 2 104 ± 3 n.s. n.s. n.s. 
 
Heart frequency [min
-1
] 598 ± 20 674 ± 15 547 ± 12 553 ± 23 n.s. P<0.01 P<0.01 
 
WT = Wild type mice 
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Table 2      eNOS-deficient mice: Echocardiographic, Hemodynamic and Morphometric Analyses 
 Sham 
eNOS 
-/-
 
Vehicle 
eNOS 
-/-
 
 Nebivolol 
eNOS 
-/-
 
Nebivolol 
WT 
P (Vehicle 
eNOS 
-/-
  
vs. Nebivolol 
eNOS 
-/-
) 
P (Nebivolol 
eNOS
-/-
 vs. 
Nebivolol WT) 
Echocardiography       
EDD [mm] 3.8 ± 0.1 5.9 ± 0.5 5.9 ± 0.2 5.2 ± 0.2 n.s. n.s. 
ESD [mm] 2.3 ± 0.1 5.3 ± 0.7 5.3 ± 0.2 4.3 ± 0.2 n.s. P<0.05 
FS [%] 39.3 ± 2.6 9.6 ± 1.9 9.6 ± 1.8 16.6 ± 2.6 n.s. P<0.05 
EF [%] 60.5 ± 4.3 19.7 ± 3.4 19.6 ± 3.2 31.7 ± 3.5 n.s. P<0.05 
 
Weights and Morphometric Analysis 
LV [mg/g body weight] 
Body weight [g] 
 
 
3.8 ± 0.1 
22 ± 0.8 
 
 
6.1 ± 0.3 
27 ± 0.5 
 
 
5.9 ± 0.4 
28 ± 0.3 
 
 
4.0 ± 0.1 
29 ± 0.5 
 
 
n.s. 
n.s. 
 
 
P<0.05 
n.s. 
LV [mg] 
 
84 ± 4 
 
162 ± 12 
 
167 ± 10 
 
114 ± 4 
 
n.s. 
 
P<0.001 
 
Cardiomyocyte cross sectional area [µm
2
] 337 ± 26 582 ± 16 
 
443 ± 11 362 ± 10 P<0.001 P<0.05 
Infarct size [%] n.a. 49 ± 2 49 ± 7 41 ± 12 n.s. n.s. 
Heart frequency [min
-1
] 549 ± 19 562 ± 27 473 ± 11 553 ± 23 P<0.05 P<0.05 
 
WT = Wild type mice 
 
